STELLA

STELLA™ is an AI-powered Multi-Parameter Optimization (MPO) drug discovery platform developed by Standigm, designed to accelerate the hit-to-lead optimization stage of drug development. By combining genetic algorithms with advanced artificial intelligence, STELLA™ enables medicinal chemists and drug discovery teams to rapidly create, refine, and optimize drug candidates with desired pharmaceutical properties.

The platform is built for pharmaceutical and biotechnology organizations seeking to streamline the progression from initial hit compounds to market-ready molecular designs. STELLA™ addresses the complexity of simultaneously optimizing multiple drug-like properties, making it a powerful tool for teams working on candidate selection and lead optimization programs.

Core Capabilities

• Multi-Parameter Optimization (MPO) enabling simultaneous optimization of multiple pharmaceutical properties in a single workflow
• Genetic algorithm-driven molecular design for efficient exploration of chemical space
• Advanced AI models to guide and accelerate drug candidate creation and refinement
• Hit-to-lead optimization support, bridging the gap between initial screening hits and viable lead compounds
• Seamless multi-objective drug design to balance competing molecular properties

Key Benefits

• Accelerates the drug candidate creation and refinement process
• Ensures swift progression from concept to market-ready molecular design
• Reduces time and resources required during the hit-to-lead optimization phase
• Supports the design of molecules with well-defined, desired pharmaceutical profiles

STELLA™ is offered by Standigm, a company focused on AI-driven new drug research and development. The platform is complemented by other Standigm AI tools, including StandigmGPT, and is supported by detailed technical documentation available via whitepaper. Organizations interested in integrating STELLA™ into their drug discovery workflows can contact Standigm directly for further information.